HER2 positive breast cancer
RecruitingStudy on Trastuzumab, Pertuzumab, and Tucatinib for Patients with Stage II-III HER2-Positive Breast Cancer Without Chemotherapy
Study on Trastuzumab, Pertuzumab, and Tucatinib for Patients with Stage II-III HER2-Positive Breast Cancer Without Chemotherapy
- Disease:HER2 positive breast cancer
- Substances:PertuzumabTrastuzumab+1
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Pertuzumab
- Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting





